for directed biosynthesis. Alteration or replacement of individual domains or modules has allowed many new polyketides to be generated with modifications at positions not readily accessible by synthetic organic chemistry.3,4)
As a starting material for the synthesis of new erythromycin analogues, we set out to generate 6-demethylerythromycins by directed biosynthesis. The 6-methyl group of erythromycin is derived from incorporation of a methylmalonyl unit by the acyltransferase in module 4 (AT4) of the 6-deoxyerythronolide B synthase (DEBS) PKS.5) Recently, REEVES and co-workers6) successfully altered the substrate specificity of AT4 in DEBS through site-specific mutagenesis to accept malonyl-CoA or methylmalonyl-CoA. The modified DEBS genes were expressed in the heterologous host Streptomyces lividans, and consequently, the aglycone 6-demethyl-6-deoxyerythronolide B was produced. RODRIGUEZ et al.7) described a novel gene delivery and expression system that allows the rapid engineering of recombinant PKSs in an erythromycin overproducing strain of Saccharopolyspora erythraea K24-1. Here, we report the use of that gene delivery system to introduce the DEBS genes harboring a mutagenized AT4 domain into S. erythraea K24-1 to produce 6-demethyl erythromycins. Compound 1 (7-hydroxy-6-demethyl-6-deoxy erythromycin D) was produced, which is demethylated at the 6-position as predicted, but unexpectedly has a hydroxyl group at the 7-position rather than at the 6-position.
In order to express the AT4-modified DEBS in S. erythraea K24-1, the genes encoding the engineered PKS (mutation 3 in reference 6) were transferred from the S. lividans expression vector to the pSET 152 integrating vector under control of the native eryAp promoter.7) The resulting vector pKOS159-42 was introduced into S. erythraea K24-1 by conjugation and the culture broths of the antibiotic-producing isolates were screened by LC/MS for the presence of compounds with mass spectra consistent with 6-demethyl-erythromycin analogues. One isolate was selected for scale-up in 10-liter bioreactors, which produced high levels of a compound with m/z 690 consistent with the mass of 6-demethyl-erythromycin D.
Each production bioreactor containing 9 liters of production medium was inoculated with 500ml of an actively growing culture of S. erythrea K24-1::pKOS159-3 liters per minute (LPM) airflow, and 600rpm agitation.
The dissolved oxygen was maintained above 40% of air saturation. A dextrin suspension (150g/liter) was fed at a rate of 5.4ml/hour throughout the cultivation. The culture broth's pH was adjusted to 8 before harvesting by centrifugation on day 6 after inoculation.
The centrifuged broth from two 10-liter bioreactors was passed over a solid-phase extraction column and eluted with methanol. LC/MS analysis of the eluate indicated at least three compounds which produced prominent ions of m/z 690. Two of these compounds were present in quantities too low for isolation; the remaining compound (1) was isolated through a combination of solid-phase extraction, liquid-liquid extraction, and reversed-phase column chromatography. Compound 1 has a molecular formula of C35H63NO12, as determined by the 13C NMR spectrum and high-resolution mass spectral data. Carbon-hydrogen connectivities were established from the multiplicity-edited HSQC spectrum, while gsCOSY and constant time HMBC data allowed tracing of the carbon-oxygen skeleton. The NMR data were consistent with a structure similar to the expected 6-demethyl-erythromycin D, but having a hydroxyl group at the 7-position rather than the 6-position. In particular, the placement of a hydroxyl group at position 7, rather than at position 6, came from HMBC correlations from H-7 to the Complete 1H and 13C NMR assignments are listed in Table   1 . The one-and two-dimensional NMR data for the rest of the molecule are consistent with the structure shown.
The antibacterial activity of compound 1, tested on Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermis, Enterococcus faecalis, and Haemophilus influenzae (Table 2) , was marginal against microorganisms that are sensitive to erythromycin A. This is not surprising since 1 lacks the 12-OH and the 3'-O-CH3 that contribute substantially to antibiotic activity.
The hydroxylation of 6-deoxyerythronolide B to erythonolide B is the first step in the pathway to convert 6-dEB into erythromycins and is catalyzed by the cytochrome
P450 oxidase
EryF8) The unexpected hydroxylation of Table 1 . The 13C and 1H NMR data for 1 (CDCl3). Table 2 . Antibacterial activity of erythromycin A and 7-hydroxy-6-demethyl-6-deoxy erythromycin D. Strain and Expression Vector S. erythraea K24-1 was described previously.7) The AT4-modified DEBS gene, which has the two AT4 amino acids adjacent to His-201 mutated (mutation 3 in reference 6), was introduced into S. erythraea K24-1 by conjugation as described previously.7) Briefly, the engineered PKS genes were transferred from the S. lividans expression vector to the pSET152 integrating vector under control of the eryAp promoter by conventional cloning procedures resulting in the vector pKOS159-42, which was introduced into S. erythraea K24-1 by conjugation. Rapamycin-resistant transconjugants were confirmed to produce compounds with antibacterial activity against M. luteus using an agar plate bioassay. Media S. erythraea K24-1::pKOS159-42 was cultivated in seed (SE-V1) and production (SE-0.5F1) media. SE-V1 contained corn starch 16g, corn dextrin 10g, soy meal flour 15g, sodium chloride 2.5g, corn steep liquor 5g, ammonium sulfate 1g, soy bean oil 6g, and calcium carbonate 4g in 1 liter of deionized water. SE-0.5F1 contained corn starch 17.5g, corn dextrin 16g, soy meal flour 16.5g, sodium chloride 3.5g, corn steep liquor 6g, and then in 63% MeOH/5mM NH4OAc, giving pools enriched in 1. Compound 1 was further purified by partitioning between ethyl acetate and saturated aqueous sodium bicarbonate, followed by C18 chromatography with a stepped gradient of 50-100% MeOH, to yield 10mg.
Minimal inhibitory concentrations (MICs) of 1 against S. pneumoniae, S. aureus, S. epidermis, E. faecalis, and H. influenzae were determined using a microdilution technique (NCCLS document M7-A5).10) Compounds were dissolved then further serially diluted 2-fold. An equal volume of cells (A600=0.1) and drug dilution were mixed to give final and MIC values were determined by visual inspection.
7-Hydroxy-6-demethyl-6-deoxy Erythromycin D (1):
Yellow solid; 10mg; UV (DAD, 50% MeCN) end 1456, 1373, 1243, 1182, 1115, 1050, 1005cm-1. 
